Daiichi Sankyo, ArQule Colorectal Cancer Drug Fails Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's colorectal cancer drug tivatinib co-developed with U.S.-based ArQule, failed a Phase II clinical trial testing improvements of survival and improved response, the companies reported.